| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Roseline I Porchet, Linde Boekhoudt, Bettina Studer, Praveen K Gandamaneni, Nisha Rani, Somashekar Binnamangala, Ulrich Müller, Luke Clar. Opioidergic and dopaminergic manipulation of gambling tendencies: a preliminary study in male recreational gamblers. Frontiers in behavioral neuroscience. vol 7. 2013-10-10. PMID:24109443. |
the objective of the current study was to assess the effects of the opioid receptor antagonist naltrexone and the dopamine d2 receptor antagonist haloperidol on gambling behavior. |
2013-10-10 |
2023-08-12 |
human |
| James B Koprich, Philippe Huot, Susan H Fox, Keith Jarvie, Anthony E Lang, Philip Seeman, Jonathan M Brotchi. The effects of fast-off-D2 receptor antagonism on L-DOPA-induced dyskinesia and psychosis in parkinsonian macaques. Progress in neuro-psychopharmacology & biological psychiatry. vol 43. 2013-09-19. PMID:23306217. |
because of the marked reduction in brain dopamine in pd and the resultant dopamine d2 receptor supersensitivity, it is impossible to use standard potent dopamine d2 receptor antagonists such as haloperidol to alleviate side effects without compromising the anti-parkinsonian benefits of l-dopa. |
2013-09-19 |
2023-08-12 |
monkey |
| Pedro Porto Alegre Baptista, Priscylla Nunes de Senna, Mariana Fontoura Paim, Lisiani Saur, Martina Blank, Patricia do Nascimento, Jocemar Ilha, Mônica Ryff Moreira Vianna, Régis Gemerasca Mestriner, Matilde Achaval, Léder Leal Xavie. Physical exercise down-regulated locomotor side effects induced by haloperidol treatment in Wistar rats. Pharmacology, biochemistry, and behavior. vol 104. 2013-09-17. PMID:23290938. |
extra-pyramidal symptoms (eps) such as akinesia, dystonia, gait alteration and tremors are observed when dopamine d2-receptors are blocked by pharmacological agents such as haloperidol. |
2013-09-17 |
2023-08-12 |
rat |
| Deborah S Kreiss, Catherine F Coffman, Nicholas R Fiacco, Jason C Granger, Bernadette M Helton, Jennifer C Jackson, Leonid V Kim, Rishi S Mistry, Tammie M Mizer, Lolita V Palmer, Jay A Vacca, Stuart S Winkler, Benjamin A Zimme. Ritualistic chewing behavior induced by mCPP in the rat is an animal model of obsessive compulsive disorder. Pharmacology, biochemistry, and behavior. vol 104. 2013-09-17. PMID:23333679. |
the effects upon the rcbs induced by mcpp (1 mg/kg) were evaluated following treatments with either the serotonin antagonist mianserin (3 mg/kg), the dopamine antagonist haloperidol (1 mg/kg), the gaba modulator diazepam (10 mg/kg), or the serotonin uptake inhibitors clomipramine and fluvoxamine (15 mg/kg). |
2013-09-17 |
2023-08-12 |
rat |
| Pei Jiang, Wen-Yuan Zhang, Huan-De Li, Hua-Lin Cai, Ying Xu. Repeated haloperidol administration has no effect on vitamin D signaling but increase retinoid X receptors and Nur77 expression in rat prefrontal cortex. Cellular and molecular neurobiology. vol 33. issue 3. 2013-09-04. PMID:23324997. |
by blocking dopamine d2 receptor, haloperidol induces nur77 expression, suggesting a modulatory role of nur77 in brain dopamine system. |
2013-09-04 |
2023-08-12 |
rat |
| Perrin Kwek, Maarten van den Buus. Modafinil disrupts prepulse inhibition in mice: strain differences and involvement of dopaminergic and serotonergic activation. European journal of pharmacology. vol 699. issue 1-3. 2013-09-02. PMID:23219987. |
this effect of modafinil could be blocked by co-treatment with the dopamine d(2) receptor antagonist, haloperidol, and the serotonin (5-ht) 2a receptor antagonist, ketanserin, but not the 5-ht(1a) receptor antagonist, way100,635. |
2013-09-02 |
2023-08-12 |
mouse |
| Tracie A Paine, Samuel K Asinof, Geoffrey W Diehl, Anna Frackman, Joseph Leffle. Medial prefrontal cortex lesions impair decision-making on a rodent gambling task: reversal by D1 receptor antagonist administration. Behavioural brain research. vol 243. 2013-08-28. PMID:23354057. |
following recovery, rats were retrained for 5 days and then the effects of a dopamine d1-like receptor antagonist (sch23390) or a d2-like receptor antagonist (haloperidol) on performance were assessed. |
2013-08-28 |
2023-08-12 |
rat |
| Maartje Luijten, Dick J Veltman, Robert Hester, Marion Smits, Lolke Pepplinkhuizen, Ingmar H A Franke. Brain activation associated with attentional bias in smokers is modulated by a dopamine antagonist. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 37. issue 13. 2013-08-26. PMID:22850734. |
haloperidol (2 mg), a selective d2/d3 dopamine antagonist, or placebo was orally administered 4 h before each scanning session in a double-blind randomized cross-over design. |
2013-08-26 |
2023-08-12 |
human |
| Jessica I Lake, Warren H Mec. Differential effects of amphetamine and haloperidol on temporal reproduction: dopaminergic regulation of attention and clock speed. Neuropsychologia. vol 51. issue 2. 2013-08-09. PMID:22982605. |
this symmetrical pattern of results suggests that clock speed is regulated by the effective level of dopamine, i.e., d-amphetamine increases clock speed and haloperidol decreases clock speed. |
2013-08-09 |
2023-08-12 |
human |
| Amanda M Isom, Gary A Gudelsky, Stephen C Benoit, Neil M Richtan. Antipsychotic medications, glutamate, and cell death: a hidden, but common medication side effect? Medical hypotheses. vol 80. issue 3. 2013-08-01. PMID:23265349. |
typical antipsychotic medications such as haloperidol elevate extracellular glutamate because they exert antagonist effects on dopamine d(2) and serotonin 5ht(1a) receptors. |
2013-08-01 |
2023-08-12 |
Not clear |
| Takashi Konishi, Satoshi Kono, Masaya Fujimoto, Tatsuhiro Terada, Kozo Matsushita, Yasuomi Ouchi, Hiroaki Miyajim. Benign hereditary chorea: dopaminergic brain imaging in patients with a novel intronic NKX2.1 gene mutation. Journal of neurology. vol 260. issue 1. 2013-06-14. PMID:22825795. |
oral levodopa failed to improve the involuntary movement, while haloperidol, a dopamine d2 receptor blocking agent, exacerbated the choric movement in a single patient. |
2013-06-14 |
2023-08-12 |
Not clear |
| Jen-Tang Cheng, Jay-Shake L. Intra-orbitofrontal cortex injection of haloperidol removes the beneficial effect of methylphenidate on reversal learning of spontaneously hypertensive rats in an attentional set-shifting task. Behavioural brain research. vol 239. 2013-06-04. PMID:23159707. |
in the present study, we manipulated orbitofrontal dopamine activities of spontaneously hypertensive rats (shr), a widely used adhd animal model, through intra-peritoneal injection of methylphenidate (mph) and central infusion of haloperidol, and observed their performances in asst. |
2013-06-04 |
2023-08-12 |
human |
| Daniela I Beiderbeck, Stefan O Reber, Andrea Havasi, Remco Bredewold, Alexa H Veenema, Inga D Neuman. High and abnormal forms of aggression in rats with extremes in trait anxiety--involvement of the dopamine system in the nucleus accumbens. Psychoneuroendocrinology. vol 37. issue 12. 2013-05-16. PMID:22608548. |
consequently, local pharmacological manipulation by infusion of an anesthetic (lidocaine, 20 μg/μl) or a dopamine d2 (haloperidol, 10 ng/μl), but not d1 (sch-23390 10 ng/μl), receptor antagonist significantly reduced high aggression in lab rats. |
2013-05-16 |
2023-08-12 |
rat |
| Robert R Luedtke, Evelyn Perez, Shao-Hua Yang, Ran Liu, Suwanna Vangveravong, Zhude Tu, Robert H Mach, James W Simpkin. Neuroprotective effects of high affinity Σ1 receptor selective compounds. Brain research. vol 1441. 2013-05-06. PMID:22285434. |
we previously reported that the antipsychotic drug haloperidol, a multifunctional d2-like dopamine and sigma receptor subtype antagonist, has neuroprotective properties. |
2013-05-06 |
2023-08-12 |
Not clear |
| G A Oganesian, E A Aristakesian, I V Romanova, S I Vataev, V V Kuzi. [On filo- and ontogenetic development of dopaminergic regylation of wakefulness-sleep cycle in vertabrates]. Rossiiskii fiziologicheskii zhurnal imeni I.M. Sechenova. vol 98. issue 10. 2013-04-29. PMID:23401916. |
administration of dopamine antagonist (haloperidol) to 30-day-old rats previously causes the increase of cataleptic state, after which the slow wave sleep state is enhanced. |
2013-04-29 |
2023-08-12 |
rat |
| Sandra M Boy. Individual phenotype predicts nicotine-haloperidol interaction in catalepsy: possible implication for the therapeutic efficacy of nicotine in Tourette's syndrome. Behavioural brain research. vol 236. issue 1. 2013-04-23. PMID:22947904. |
in laboratory rats, the dopamine antagonist haloperidol produces catalepsy and nicotine can potentiate it, although this effect is variable and not always observed. |
2013-04-23 |
2023-08-12 |
rat |
| Yeon Won Park, Yooseok Kim, Jun Ho Le. Antipsychotic-induced sexual dysfunction and its management. The world journal of men's health. vol 30. issue 3. 2013-04-19. PMID:23596605. |
based on the blockade of dopamine d2 receptors, haloperidol, risperidone, and amisulpride are classed as prolactin-elevating antipsychotics, while olanzapine, clozapine, quetiapine, ziprasidone, and aripiprazole are classed as prolactin-sparing drugs. |
2013-04-19 |
2023-08-12 |
Not clear |
| Francesca Managò, Stefano Espinoza, Ali Salahpour, Tatyana D Sotnikova, Marc G Caron, Richard T Premont, Raul R Gainetdino. The role of GRK6 in animal models of Parkinson's disease and L-DOPA treatment. Scientific reports. vol 2. 2013-04-12. PMID:22393477. |
to understand how grk6 modulates the behavioral manifestations of dopamine deficiency and responses to l-dopa, we used three approaches to model pd in grk6-ko mice: 1) the cataleptic response to haloperidol; 2) introducing grk6 mutation to an acute model of absolute dopamine deficiency, ddd mice; 3) hemiparkinsonian 6-ohda model. |
2013-04-12 |
2023-08-12 |
mouse |
| Sergi Mas, Patricia Gassó, Gemma Trias, Miquel Bernardo, Amalia Lafuent. Sulforaphane protects SK-N-SH cells against antipsychotic-induced oxidative stress. Fundamental & clinical pharmacology. vol 26. issue 6. 2013-03-28. PMID:21923690. |
human neuroblastoma sk-n-sh cells were treated with sf (0.5-5 μm), and 24 h later, haloperidol, risperidone or paliperidone (100 μm) was administered, either alone or in combination with dopamine (100 μm). |
2013-03-28 |
2023-08-12 |
human |
| Rajeev I Desai, Ganesh A Thakur, V Kiran Vemuri, Shama Bajaj, Alexandros Makriyannis, Jack Bergma. Analysis of tolerance and behavioral/physical dependence during chronic CB1 agonist treatment: effects of CB1 agonists, antagonists, and noncannabinoid drugs. The Journal of pharmacology and experimental therapeutics. vol 344. issue 2. 2013-03-28. PMID:23197773. |
in the present studies, the effects of cb(1) agonists [(6ar,10ar)-3-(1-adamantyl)-6,6,9-trimethyl-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol (am411), 9β-(hydroxymethyl)-3-(1-adamantyl)-hexahydrocannabinol (am4054), r-(+)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone mesylate (win55,212.2), Δ(9)-tetrahydrocannabinol (Δ(9)-thc), (r)-(+)-arachidonyl-1'-hydroxy-2'-propylamide (methanandamide)], cb(1) antagonists [5-(4-chlorophenyl)-1-(2,4-dichloro-phenyl)-4-methyl-n-(piperidin-1-yl)-1h-pyrazole-3-carboxamide (sr141716a), 5-(4-alkylphenyl)-1-(2,4-dichlorophenyl)-4-methyl-n-(piperidin-1-yl)-1h-pyrazole-3-carboxamide (am4113)], and dopamine (da)-related [methamphetamine, (±)-6-chloro-7,8-dihydroxy-3-allyl-1-phenyl-2,3,4,5-tetrahydro-1h-3-benzazepine hydrobromide (skf82958), (r)-(+)-7-chloro-8-hydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1h-3-benzazepine hydrochloride (sch23390), (6ar)-5,6,6a,7-tetrahydro-6-propyl-4h-dibenzo[de,g]quinoline-10,11-diol (r-(-)-npa), haloperidol] and opioid (morphine, naltrexone) drugs on scheduled-controlled responding under a 30-response fixed ratio schedule of stimulus-shock termination in squirrel monkeys were compared before and during chronic treatment with the long-acting cb(1) agonist am411 (1.0 mg/kg per day, i.m.). |
2013-03-28 |
2023-08-12 |
monkey |